drugset / Trial / NCT05466474
PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
A total of 40 subjects who had not received systemic treatment or chemotherapy in the past and were allowed to receive adjuvant or neoadjuvant treatment for advanced melanoma received tirelizumab combined with dacarbazine for 4-6 cycles to evaluate the efficacy, safety and prognosis of tirelizumab combined with dacarbazine in the treatment of advanced melanoma.
Timeline
- Start
- 2022-12-30
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |